$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

Kisqali Six Year Data Show Survival Benefit Holds

Six years into the phase 3 NATALEE trial, patients who took ribociclib with hormone therapy after early breast cancer surgery were alive at a rate of 91.9 percent, against 89.7 percent on hormone therapy alone.

TML Health DeskNov 18, 4:08 PM ET · 2 min read

Edited and fact-checked by Stephen Sprague

A cancer research centre (archive). Photo: fboudville, via Flickr (CC BY-SA).
Summary

The nodal subgroup analysis at the San Antonio symposium on December 9 shows whether the six-year benefit reaches the node-negative patients the trial enrolled.

Tap a passage. React to the part that matters.

The six-year analysis of the NATALEE trial landed at the ESMO Congress in Madrid with 5,101 patients behind it. NATALEE is a randomized phase 3 trial in stage II and III hormone receptor positive, HER2 negative early breast cancer at high risk of recurrence, and it tested ribociclib, sold as Kisqali, added to a nonsteroidal aromatase inhibitor against the hormone therapy alone.

At a median follow-up of 66.5 months, 91.9 percent of the 2,549 patients in the ribociclib arm were alive at six years, against 89.7 percent of the 2,552 patients in the control arm. The absolute difference is 2.1 percentage points, and the hazard ratio for death is 0.809. Six-year invasive disease-free survival was 83.2 percent against 77.9 percent, with a hazard ratio of 0.741, and breast cancer specific survival also favored ribociclib at a hazard ratio of 0.706.

Every patient in this analysis had already finished the drug, with a median of 38 months off treatment at the time of the reading. The survival gap therefore reflects a benefit that held after the ribociclib course ended, and the investigators reported no new safety signals in the longer follow-up.

Hope Rugo, who directs the Women's Cancers Program at City of Hope, told OncLive the results are on par with the phase 3 monarchE trial data for another drug in the same class. She pointed to the enrollment itself as the trial's contribution, because NATALEE included intermediate-risk patients whose cancer had not spread to their lymph nodes, a group often offered less intensive therapy after surgery.

The limits of the analysis sit inside its own statistics, since the survival comparison rests on a nominal one-sided P value of .019 and the trial tested a single combination in a defined high-risk population. The result says nothing about low-risk patients or other cancers, and survival follow-up is still running.

Novartis, which makes Kisqali, announced on Wednesday, November 18, that a NATALEE analysis broken out by nodal status will be presented as a late-breaking poster at the San Antonio Breast Cancer Symposium on December 9. That subgroup reading is the next test of how evenly the six-year benefit is spread.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.